DexCom, Inc. (DXCM) Net Income
The annual net income for DexCom, Inc. (DXCM) is $836.30 Million with a year-over-year change of +45.14%. Net income represents the company's bottom line profit after all expenses, taxes, and interest.
Annual Net Income (TTM)
$836.30M
$836.30 Million
Year-over-Year Change
+45.14%
vs. $576.20M prior year
Net Income CAGR
+12.60%
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
+73.91%
3 Year
+47.05%
5 Year
+12.60%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $836.30M | +$260.10M | +45.14% |
| 2024 | $576.20M | +$34.70M | +6.41% |
| 2023 | $541.50M | +$200.30M | +58.70% |
| 2022 | $341.20M | +$124.30M | +57.31% |
| 2021 | $216.90M | ($276.70M) | (56.06%) |
| 2020 | $493.60M | +$392.50M | +388.23% |
| 2019 | $101.10M | +$228.20M | — |
| 2018 | ($127.10M) | ($76.90M) | — |
| 2017 | ($50.20M) | +$15.40M | — |
| 2016 | ($65.60M) | ($8.00M) | — |
Net Income Growth Summary
TTM Growth
+73.91%
3-Year Avg Growth
+47.05%
5-Year Avg Growth
+12.60%
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach